Novel treatments for dry eye syndrome

• Published in: Current opinion in pharmacology 2024-04, Vol.75, p.102431-102431, Article 102431
• Main Authors: Roucaute, Esther, Huertas-Bello, Marcela, Sabater, Alfonso L.
• Format: Article
• Language: English
• Subjects: Dry Eye Syndromes - diagnosis; Dry Eye Syndromes - drug therapy; Dry Eye Syndromes - etiology; Eye; Humans; Inflammation - complications; Quality of Life; Treatment Outcome
• ISSN: 1471-4892; 1471-4973
• DOI: 10.1016/j.coph.2024.102431

Dry eye syndrome (DES) is a prevalent and multifactorial disease that leads to a self-perpetuating cycle of inflammation and damage to the ocular surface. This results in symptoms such as redness, burning, and blurred vision, which can negatively affect a patient's quality of life. While treatments are available to manage DES, they only temporarily relieve symptoms. Furthermore, long-term use of certain medications can cause harm to the ocular surface. Therefore, there is a need for safer and effective treatments for DES. This review highlights the latest advancements in DES therapy, providing valuable insights into ongoing efforts to improve patient outcomes. •Dry eye syndrome is a prevalent condition that can significantly impact patients' quality of life.•Traditional treatments for dry eye syndrome, such as lubricating eye drops, may not be effective for all patients.•A better understanding of the pathophysiology of dry eye disease has led to novel therapies targeting new pathways.